How to buy Verona Pharma stock

Verona Pharma plc is a biotechnology business based in the US. Verona Pharma shares (VRNA) are listed on the NASDAQ and all prices are listed in US Dollars. Verona Pharma employs 25 staff and has a market cap (total outstanding shares value) of 0.00.

Verona Pharma share price

Use our graph to track the performance of VRNA stocks over time.

Verona Pharma shares at a glance

• Key figures

Information last updated 2021-04-23.

52-week range	$3.70 - $9.72
50-day moving average	$8.39
200-day moving average	$7.61
Wall St. target price	$19.20
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.34

Buy Verona Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Verona Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Verona Pharma plc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Verona Pharma financials

Gross profit TTM	$0
Return on assets TTM	-30.24%
Return on equity TTM	-57.25%
Profit margin	0%
Book value	$3.19
Market capitalisation	$434.3 million

TTM: trailing 12 months

Shorting Verona Pharma shares

There are currently 110,136 Verona Pharma shares held short by investors – that's known as Verona Pharma's "short interest". This figure is 12.3% up from 98,104 last month.

There are a few different ways that this level of interest in shorting Verona Pharma shares can be evaluated.

Verona Pharma's "short interest ratio" (SIR)

Verona Pharma's "short interest ratio" (SIR) is the quantity of Verona Pharma shares currently shorted divided by the average quantity of Verona Pharma shares traded daily (recently around 93335.593220339). Verona Pharma's SIR currently stands at 1.18. In other words for every 100,000 Verona Pharma shares traded daily on the market, roughly 1180 shares are currently held short.

However Verona Pharma's short interest can also be evaluated against the total number of Verona Pharma shares, or, against the total number of tradable Verona Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Verona Pharma's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Verona Pharma shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Verona Pharma shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Verona Pharma.

Find out more about how you can short Verona Pharma stock.

Verona Pharma share dividends

We're not expecting Verona Pharma to pay a dividend over the next 12 months.

Verona Pharma share price volatility

Over the last 12 months, Verona Pharma's shares have ranged in value from as little as $3.7 up to $9.722. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Verona Pharma's is 0.5747. This would suggest that Verona Pharma's shares are less volatile than average (for this exchange).

Verona Pharma overview

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 2 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. It also focuses on developing ensifentrine for the treatment of COVID-19. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom. .

Frequently asked questions

• What percentage of Verona Pharma is owned by insiders or institutions?

  Currently 1.33% of Verona Pharma shares are held by insiders and 67.457% by institutions.

• How many people work for Verona Pharma?

  Latest data suggests 25 work at Verona Pharma.

• When does the fiscal year end for Verona Pharma?

  Verona Pharma's fiscal year ends in December.

• Where is Verona Pharma based?

  Verona Pharma's address is: 3 More London Riverside, London, United Kingdom, SE1 2RE

• What is Verona Pharma's ISIN number?

  Verona Pharma's international securities identification number is: US9250501064

• What is Verona Pharma's CUSIP number?

  Verona Pharma's Committee on Uniform Securities Identification Procedures number is: 925050106